BMC Pediatr. 2026 Nov 21;26(1):1212. doi: 10.1186/s12887-026-07978-x.
ABSTRACT
BACKGROUND: Environmental enteropathy (EE) is an acquired subclinical inflammation of the small bowel mucosa, leading to reduced nutrient absorption and increased intestinal permeability. There are currently no universally accepted protocols for the diagnosis and treatment of EE.
OBJECTIVE: The primary aim of this clinical trial was to assess the prevalence of EE among children with faltering growth (FG). Determination of the dietary requirements in pediatric FG with EE and highlighting the histopathologic changes in the small intestine in such conditions were the secondary objectives.
PATIENTS AND METHODS: The current study recruited 200 patients (their age range was 6-58 months) diagnosed as GF at the Pediatric Clinical Nutrition Clinic, Children`s Hospital, Faculty of Medicine, Ain Shams University (Cairo, Egypt), during the period from April 2022 till June 2023. The first phase of the study was a cross sectional interventional one where all patients underwent nutritional rehabilitation using diet regimen including polymeric milk formula. Patients whose weight z score was still below — 2 SD for age and sex after 12 weeks were considered as non-responders and were enrolled in the second phase, when esophagogastroduodenoscopy (EGD) and mucosal biopsies were done. In the latter phase, patients with EE received nutritional rehabilitation regimen using peptide-based milk formula with assessment of anthropometric measurements after 8 weeks of follow up.
RESULTS: Out of the studied cases, 170 were responders, and 30 were non-responders, 24 of the non-responders underwent EGD with biopsies and all were diagnosed as EE with prevalence of 12% among the studied patients with GF as the least possible prevalence. Total histology scores of the EE fell between those of the controls and celiac disease reference samples with cut off values > 3 and ≤ 14 for EE, ≤ 3 for controls and > 14 for celiac disease. There was a significant increase in weight and height z scores among patients of EE on peptide-based formula compared to polymeric formula.
CONCLUSION: EE isn`t uncommon and should be suspected when provision of catch-up nutrients can`t correct FG. Peptide-based formula has a possible beneficial effect on growth of patients with EE.
TRIAL REGISTRATION: The clinical trial was registered at Protocol Registration and Results System with number NCT06497907 (12/07/2024).
PMID:43064953 | DOI:10.1186/s12887-026-07978-x
